Vistel

Vistel is a national high-tech enterprise specializing in the application of artificial intelligence in the medical industry, particularly in the field of ophthalmology. It is committed to empowering medical institutions at all levels with advanced technology to enhance diagnostic capabilities and efficiency, enabling the general public to access more equitable, accessible, and continuous healthcare services close to home. Vistel provides professional, integrated hardware and software AI solutions for various scenarios in ophthalmic care, earning recognition from top-tier ophthalmology teams at renowned tertiary hospitals such as Peking Union Medical College Hospital, Tongren Hospital, Shanghai Eye Disease Prevention Center, Zhongshan Hospital, and the First Affiliated Hospital of Zhengzhou University. Its solutions have been clinically applied in over 1,800 medical institutions across China for primary screening, auxiliary diagnosis, and treatment of common blinding fundus diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration, serving more than one million patients cumulatively. Vistel boasts a complete, innovative R&D system with independent intellectual property rights and deep technological expertise, having published 33 academic papers in top industry journals and conferences, including one journal cover article. The company has obtained over 60 software copyrights and 22 patents. Its self-developed AI-based software for auxiliary diagnosis of diabetic retinopathy was the first to receive Class III medical device certification from China’s National Medical Products Administration (NMPA) and EU CE certification. Its multi-disease fundus imaging auxiliary diagnostic software was the first to be approved by the NMPA for entry into the "Special Review Procedure for Innovative Medical Devices" and is the world's only multi-disease auxiliary diagnostic software with EU CE certification. Currently, its products have achieved large-scale commercial deployment in France, Germany, Spain, Italy, and other countries, receiving high praise from partners.